Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06641466 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

StatusRecruiting
PhasePhase 3
SponsorPfizer
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 5 of 123 sitesv37
  2. Study sites: 122 to 123v36
  3. Study sites revised (122)v35 See this version in full on ClinicalTrials.gov ↗
  4. Site details revised at 1 of 122 sitesv34
  5. Site details revised at 4 of 122 sitesv33
Show 31 earlier versionsHide 31 earlier versions
  1. Site details revised at 1 of 122 sitesv32
  2. Study sites: 115 to 122v31
  3. Site details revised at 2 of 115 sitesv30
  4. Study sites: 114 to 115v29
  5. Study sites: 107 to 114v28
  6. Study sites: 102 to 107v27
  7. Study sites: 95 to 102v26
  8. Study sites: 85 to 95v25
  9. Study sites: 78 to 85v24
  10. Study sites: 66 to 78v23
  11. Study sites: 61 to 66v22
  12. Study sites: 60 to 61v21
  13. Study sites: 58 to 60v20
  14. Site details revised at 5 of 58 sitesv19
  15. Study sites: 56 to 58v18
  16. Study sites: 55 to 56v17
  17. Study sites: 46 to 55v16
  18. Study sites: 44 to 46v15
  19. Study sites: 37 to 44v14
  20. Study sites: 34 to 37v13
  21. Study sites: 30 to 34v12
  22. Site details revised at 2 of 30 sitesv11
  23. Study sites: 24 to 30 Completion date: Nov 29, 2026 to Mar 30, 2027v10 Show 1 more changeShow less
    • Completion date: Nov 29, 2026 to Mar 30, 2027
  24. Study sites: 12 to 24v9
  25. Study sites: 8 to 12v8
  26. Study sites: 5 to 8 Primary and study completion dates: Dec 1, 2026 to Nov 29, 2026 · Start date changed from estimate of Mar 13, 2025 to Mar 11, 2025v7 Show 2 more changesShow less
    • Primary and study completion dates: Dec 1, 2026 to Nov 29, 2026
    • Start date changed from estimate of Mar 13, 2025 to Mar 11, 2025
  27. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 5 · Primary and study completion dates: Dec 2, 2026 to Dec 1, 2026 · Start date: Mar 2025 to Mar 13, 2025v6 Show 3 more changesShow less
    • Study sites: 0 to 5
    • Primary and study completion dates: Dec 2, 2026 to Dec 1, 2026
    • Start date: Mar 2025 to Mar 13, 2025
  28. Primary and study completion dates: Dec 29, 2026 to Dec 2, 2026 Start date: Feb 21, 2025 to Mar 2025v5 Show 1 more changeShow less
    • Start date: Feb 21, 2025 to Mar 2025
  29. Start date: Feb 3, 2025 to Feb 21, 2025v4
  30. Start date: Dec 24, 2024 to Feb 3, 2025 Primary and study completion dates: Sep 13, 2026 to Dec 29, 2026v3 Show 1 more changeShow less
    • Primary and study completion dates: Sep 13, 2026 to Dec 29, 2026
  31. Primary completion date: Jun 3, 2026 to Sep 13, 2026 Completion date: Sep 24, 2026 to Sep 13, 2026 · Start date: Nov 29, 2024 to Dec 24, 2024v2 Show 2 more changesShow less
    • Completion date: Sep 24, 2026 to Sep 13, 2026
    • Start date: Nov 29, 2024 to Dec 24, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
433 trials monitored
See 31 trials at risk
Migraine
467 trials monitored
See 24 trials at risk
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
Trial Details
NCT Number NCT06641466
Lead Sponsor Pfizer
Conditions Menstrual Migraine
Enrollment 723 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov